Short Interest in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Increases By 232.0%

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) was the target of a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 540,900 shares, an increase of 232.0% from the February 13th total of 162,900 shares. Approximately 81.8% of the shares of the company are short sold. Based on an average daily trading volume, of 1,740,000 shares, the short-interest ratio is currently 0.3 days.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of TransCode Therapeutics in a research note on Thursday.

TransCode Therapeutics Stock Up 4.8 %

TransCode Therapeutics stock traded up $0.04 during trading hours on Friday, hitting $0.78. 12,758,237 shares of the company traded hands, compared to its average volume of 2,951,627. The firm’s 50-day simple moving average is $5.59 and its two-hundred day simple moving average is $239.68. TransCode Therapeutics has a 1-year low of $0.65 and a 1-year high of $66.33.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.